Mid career · publishing since 2004Rising activity
Head and Neck Cancer StudiesMRI in cancer diagnosisCancer Diagnosis and TreatmentHepatocellular Carcinoma Treatment and PrognosisNanoplatforms for cancer theranostics
Publications
61
Citations
5,224
Est. group size
—
Recurring co-author estimate
Active years
22
Publishing since 2004
In context
Among 4,491 mid career Medicine PIs within our index
Citations: 5,224p25 240 · p75 1,552 · cohort median 614
Publications / year (recent): 3.4p25 1.8 · p75 7.2 · cohort median 3.4
Typically publishes in teams of ~10 · 0% small-team papers (≤3 authors) · across 5 venues
Publication cadence
Publications per year over the last 10 years — averaging 3.4/year recently
Collaborators per year
Distinct co-authors at University of Michigan each year — a rough indication of whether the group around this researcher has been growing or contracting. An estimate from co-authorship, not a roster: collaborators are not necessarily lab members, and recent years can be under-counted while indexing catches up.
Recent publications
- Workflow and Treatment Volumes for UMCC2023.006: A Pilot Phase II Trial of Individualized FDG-PET and DCE-MRI Directed Adaptive RT in HPV-related Stage III Oropharynx Cancer (OPSCC)
International Journal of Radiation Oncology*Biology*Physics · 2025
- 879P VERSATILE-002: Survival with first-line treatment with PDS0101 therapeutic vaccine and pembrolizumab in HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma (HNSCC)
Annals of Oncology · 2024
- Imaging Metrics and HPV ctDNA Kinetics in a Phase II Immuno-Chemoradiation Trial for Locoregionally Advanced p16+ Oropharynx Cancer
International Journal of Radiation Oncology*Biology*Physics · 2024
- Supplementary Methods, Figure Legends 1-4 from Metronomic Dosing of BH3 Mimetic Small Molecule Yields Robust Antiangiogenic and Antitumor Effects
2023
- Supplementary Figure 2 from Metronomic Dosing of BH3 Mimetic Small Molecule Yields Robust Antiangiogenic and Antitumor Effects
2023
- Supplementary Figure 1 from Metronomic Dosing of BH3 Mimetic Small Molecule Yields Robust Antiangiogenic and Antitumor Effects
2023
- Data from Metronomic Dosing of BH3 Mimetic Small Molecule Yields Robust Antiangiogenic and Antitumor Effects
2023
- Supplementary Figure 4 from Metronomic Dosing of BH3 Mimetic Small Molecule Yields Robust Antiangiogenic and Antitumor Effects
2023
- Supplementary Methods, Figure Legends 1-4 from Metronomic Dosing of BH3 Mimetic Small Molecule Yields Robust Antiangiogenic and Antitumor Effects
2023
- Supplementary Figure 4 from Metronomic Dosing of BH3 Mimetic Small Molecule Yields Robust Antiangiogenic and Antitumor Effects
2023
- Supplementary Figure 3 from Metronomic Dosing of BH3 Mimetic Small Molecule Yields Robust Antiangiogenic and Antitumor Effects
2023
- Supplementary Figure 3 from Metronomic Dosing of BH3 Mimetic Small Molecule Yields Robust Antiangiogenic and Antitumor Effects
2023
- Data from Metronomic Dosing of BH3 Mimetic Small Molecule Yields Robust Antiangiogenic and Antitumor Effects
2023
- Supplementary Figure 2 from Metronomic Dosing of BH3 Mimetic Small Molecule Yields Robust Antiangiogenic and Antitumor Effects
2023
- Supplementary Figure 1 from Metronomic Dosing of BH3 Mimetic Small Molecule Yields Robust Antiangiogenic and Antitumor Effects
2023
Publishes in
- International Journal of Radiation Oncology*Biology*Physics×10
- Journal of the National Comprehensive Cancer Network×4
- Annals of Oncology×2
- Oral Oncology×1
- Archives of Pathology & Laboratory Medicine×1
Similar researchers
By research-topic overlap
- Madhava Aryal
Medicine · University of Michigan
- E. Ozer
Medicine · The Ohio State University
- Ashok Srinivasan
Medicine · University of Michigan
- Min Liu
Medicine · University of Michigan
- Shelby P. Unsworth
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile